Authors

Latest:

Lori Sakoda on Genetic Risk Variants for COPD and Lung Cancer

Lori C. Sakoda, PhD, research scientist at Kaiser Permanente Division of Research and affiliate investigator of the Division of Public Health Sciences at the Fred Hutchinson Cancer Research Center, discusses her study examining the pleiotropic associations of genetic risk variants for chronic obstructive pulmonary disease (COPD) with lung cancer risk.

Lori J. Goldstein, MD

Latest:

Dr. Lori Goldstein on Neoadjuvant Treatment for HER2+ Breast Cancer

Lori Goldstein, MD, the director of the Naomi and Phil Lippincott Breast Evaluation Center, Fox Chase Cancer Center, discusses a neoadjuvant trial of lapatinib and trastuzumab with or without endocrine therapy for 12 weeks vs. 24 weeks in patients with HER2 overexpressing breast cancer.

Lori J. Wirth, MD

Latest:

Dr Wirth on the Safety of Selpercatinib in RET Fusion+ Thyroid Cancer

Lori Wirth, MD, discusses the safety selpercatinib in adult or pediatric patients with advanced or metastatic RET fusion–positive thyroid cancer.

Lorraine Fernandes, RHIA

Latest:

Interoperability Is the Key to a Patient-centric Transformation of the Healthcare System

Healthcare data trapped in non-interoperable clinical systems leads to flawed processes, inefficient workflow, and less-than-optimal care.

Lorraine M. Cherry, PhD

Latest:

Krebs Cycle: A Role for Metabolic Enzymes in Acute Myeloid Leukemia

One promising avenue of exploration of biomarkers in AML is the Krebs cycle, where inhibiting a key metabolic enzyme has proved beneficial in early clinical studies.

Lorraine Pelosof, MD, PhD

Latest:

NSCLC Emerging as a Growing Problem Among Never-Smokers

A substantialâ€”and potentially growingâ€”proportion of patients with nonâ€“small cell lung cancer are people who never, or only rarely, smoked.

Lou

Louis

Louis B. Nabors, MD

Latest:

Dr. Nabors on Evolving Treatment Options for Brain Metastases

Louis B. Nabors, MD, of University of Alabama, Birmingham Comprehensive Cancer Center, discusses the evolving treatment landscape for patients with brain metastases.

Louis M. Weiner, MD

Latest:

Dr. Weiner on the Criteria Required to Become an NCI-Designated Cancer Center

Louis M. Weiner, MD, director of the Georgetown Lombardi Comprehensive Cancer Center, discusses the criteria required to become an NCI-designated cancer center.

Louis S. Constine, MD

Latest:

Combined Radiation Therapy and Checkpoint Inhibition in Lymphoma: A Case Report and Brief Review

The emergence of immune checkpoint inhibitors as an effective treatment strategy is a result of increased understanding of the elaborate relationship between tumor cells, their microenvironment and the host immune response.

Lowell Anthony, MD

Latest:

Dr. Anthony on the Pathology of Neuroendocrine Tumors

Lowell Anthony, MD, chief, Division of Medical Oncology, University of Kentucky Markey Cancer Center, discusses the various subtleties in defining the pathology of neuroendocrine tumors.

Lowell B. Anthony, MD

Latest:

Dr. Anthony on Treatment Benefit With Telotristat Epitrate in Patients With Carcinoid Syndrome

Lowell B. Anthony, MD, professor of Medicine, University of Kentucky, discusses patient exit interviews from the phase III placebo-controlled TELESTAR trial, which evaluated telotristate epitrate in patients with inadequately controlled carcinoid syndrome.

Lowell B. Anthony, MD, FACP

Latest:

Dr. Anthony on Spartalizumab in NETs

Lowell B. Anthony, MD, FACP, chief, Division of Medical Oncology, University of Kentucky Markey Cancer Center, discusses preliminary research with spartalizumab (PDR001) in neuroendocrine tumors (NETs).

Lowell L. Hart, MD

Latest:

Dr. Hart on Personalized Treatment Approach for Patients With HER2+ Breast Cancer

Lowell L. Hart, MD, discusses personalized treatment approaches for patients with HER2-positive breast cancer.

Lowell L. Hart, MD, FACP

Latest:

Dr. Hart on Detecting and Treating Interstitial Lung Disease in HER2+ Breast Cancer

Lowell L. Hart, MD, FACP, discusses detection and treatment of interstitial lung disease for patients with HER2-positive breast cancer who received fam-trastuzumab deruxtecan-nxki.

Luciano J. Costa, MD, PhD

Latest:

Dr Costa on the Clinical Implications of the MASTER Trial in Multiple Myeloma

Luciano J. Costa, MD, PhD, discusses clinical implications derived from a final analysis of the phase 2 MASTER trial, which evaluated quadruplet induction therapy in multiple myeloma.

Luciano Mutti, MD

Latest:

Dr. Mutti on Current Role of Immunotherapy for Mesothelioma

Luciano Mutti, MD, professor of Cancer Research, University of Salford Manchester, discusses the current role of immunotherapy for patients with mesothelioma.

Lucio CrinÃ², MD

Latest:

Dr. CrinÃ² on Crizotinib in ALK-Positive NSCLC

Lucio CrinÃ², MD, discusses the results of the PROFILE 1007 trial that compared crizotinib with standard chemotherapy as second-line therapy for advanced ALK+ non-small cell lung cancer

Lucy Langer, MD

Latest:

CMS Should Broaden Coverage for Germline Mutation Testing

Sometimes referred to as massively parallel sequencing, next-generation sequencing evaluates millions of DNA sequences simultaneously, representing a true revolution compared with traditional, labor-intensive methods in which far less DNA could be sequenced at once.